HUTCHMED Announces Positive Phase III Data for Sovleplenib in Warm Autoimmune Hemolytic Anemia (wAIHA) at EHA 2026
Key Highlights and Investor Implications
- Breakthrough Phase III Results for Sovleplenib in wAIHA
- China NDA Accepted and Granted Priority Review; Breakthrough Therapy Designation Received
- Potential First-in-Class Targeted Therapy in a Major Unmet Medical Need
- Strong Efficacy and Safety Profile with Potential to Transform Patient Outcomes
- Presentation Selected for Official EHA Press Program
Full Article
HUTCHMED (China) Limited has announced highly promising results from the Phase III portion of its ESLIM-02 study of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) in China. These results were unveiled at the European Hematology Association (EHA) Congress in Stockholm on June 11, 2026, and represent a potentially transformative development for both patients and shareholders.
Key Clinical Results
- Study Design: ESLIM-02 is a randomized, double-blind, placebo-controlled Phase II/III study involving adults with primary or secondary wAIHA who had relapsed or were refractory to at least one prior line of standard treatment.
- Patient Population: 90 patients randomized 1:1 to receive either sovleplenib (n=44) or placebo (n=46) at 300 mg daily for 24 weeks.
- Primary Endpoint Met: Sovleplenib achieved a significantly higher durable hemoglobin response rate during weeks 5–24 vs. placebo (66% vs. 15%, p<0.0001).
- Overall Response Rate: Sovleplenib group saw a 70% overall response rate (hemoglobin ≥100 g/L and increase ≥20 g/L without rescue therapy), compared to 22% for placebo (p<0.0001).
- Reduced Need for Rescue Therapies: Significant reduction in protocol-defined rescue therapy (16% vs 54%, p=0.0001).
- Fewer Blood Transfusions: Only 11% of sovleplenib patients required transfusions versus 43% with placebo.
- Greater Glucocorticoid Tapering/Discontinuation: 50% vs 15% (p=0.003).
- Faster and More Durable Responses: Median time to response: 3.1 weeks (sovleplenib) vs 6.3 weeks (placebo). Median cumulative duration of response: 16.1 weeks (sovleplenib) vs 6.1 weeks (placebo).
- Consistent Benefits: Efficacy consistent across all patient subgroups, including those previously treated with rituximab (durable response 69% vs 16%, p=0.0022).
Safety Profile
- Favorable Safety: Grade ≥3 treatment-emergent adverse events (TEAEs) reported in 43% of sovleplenib patients vs 59% in placebo.
- Most Common Severe TEAEs: Warm AIHA (18% sovleplenib vs 43% placebo), upper respiratory tract infection (2% vs 11%).
- No TEAE-Related Deaths or Discontinuations: No deaths or discontinuations due to TEAEs in sovleplenib group.
Regulatory and Market Status
- NDA Status: China National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) for sovleplenib in wAIHA and granted priority review in April 2026.
- Breakthrough Therapy Designation: NMPA granted this designation in March 2026, reflecting the urgent need and potential impact.
- HUTCHMED Retains Global Rights: All worldwide rights to sovleplenib are retained by HUTCHMED, preserving significant future value.
Wider Pipeline and Market Implications
- Potential First Approved Targeted Therapy in wAIHA: There are currently no approved targeted therapies for wAIHA, making sovleplenib a potential first-in-class product with significant market potential if approved.
- Expansion in Immune Thrombocytopenia (ITP): Sovleplenib also demonstrated positive Phase III results in ITP; NDA for ITP is under priority review in China (as of Feb 2026).
- Large Patient Populations: In China alone, 430,000 existing ITP patients and 41,000 new ITP cases per year; about half do not respond adequately to current treatments.
Expert Commentary
Professor Bing Han, of Peking Union Medical College Hospital, co-lead investigator, noted: “The wAIHA treatment paradigm has remained stagnant for decades, with patients often trapped in a cycle of high-dose steroids and frequent relapses… Targeting the Syk pathway can achieve both rapid and durable control of hemolysis. Sovleplenib’s ability to significantly reduce the need for rescue therapies and blood transfusions represents a major step forward in restoring quality of life.”
Implications for Shareholders
- Major Price-Sensitive Event: These results, along with regulatory momentum (priority review, Breakthrough Therapy status), position sovleplenib as a potentially transformative portfolio asset for HUTCHMED. Approval could unlock a large, untapped market in both wAIHA and ITP where current therapies are inadequate.
- Potential for Global Expansion: As HUTCHMED retains worldwide rights, success in China could facilitate global regulatory submissions and commercial partnerships, driving further share price upside.
- Risk Factors: Investors should note standard clinical and regulatory risks, though the breakthrough and priority review designations help de-risk the approval process.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is a commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases. It currently markets three medicines in China and has global regulatory approvals for its first product.
Disclaimer
Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information is based on company disclosures as of June 2026. Investors should consider all publicly available information and consult professional advisors before making investment decisions. Past performance is not indicative of future results.
和黃醫藥（HUTCHMED）於EHA 2026發表Sovleplenib治療溫抗體自身免疫性溶血性貧血（wAIHA）三期臨床數據
重點摘要及對投資者影響
- Sovleplenib治療wAIHA三期臨床數據突破
- 中國新藥申請（NDA）已獲受理及優先審評；同時獲「突破性治療」認定
- 有望成為首個針對wAIHA的靶向治療，填補市場空白
- 療效顯著，安全性良好，或改變現有治療格局
- 獲選EHA官方新聞發佈項目
詳盡報導
和黃醫藥（HUTCHMED）於2026年6月11日於斯德哥爾摩舉行的歐洲血液學協會（EHA）年會上，公佈旗下創新藥物Sovleplenib治療溫抗體自身免疫性溶血性貧血（wAIHA）中國成人患者的三期臨床數據，引起行業及資本市場高度關注，為集團血液學產品線帶來重大里程碑。
臨床數據詳情
- 研究設計： ESLIM-02為隨機、雙盲、安慰劑對照的中國二/三期臨床研究，對象為對至少一線標準治療後復發/難治的wAIHA成人患者。
- 受試者： 90名患者，1:1隨機分配Sovleplenib（n=44）或安慰劑（n=46），每日口服300mg，治療24週。
- 主要終點達標： Sovleplenib在第5-24週持續血紅蛋白反應率明顯高於安慰劑（66%對15%，p<0.0001）。
- 總反應率： Sovleplenib組達到70%（血紅蛋白≥100g/L且較基線升高≥20g/L且無需救援治療），安慰劑僅22%（p<0.0001）。
- 顯著減少救援治療： Sovleplenib組救援治療比率僅16%，安慰劑組高達54%（p=0.0001）。
- 輸血需求大幅下降： 需紅血球輸血患者比例：Sovleplenib組11%，安慰劑組43%。
- 可減少或停用糖皮質激素： Sovleplenib組有50%患者可減量/停用基線治療，安慰劑僅15%（p=0.003）。
- 反應更快且持久： 中位起效時間3.1週（Sovleplenib）對6.3週（安慰劑）；反應持續時間分別為16.1週對6.1週。
- 各亞組療效一致： 包括曾用過Rituximab的患者，持續反應率69%對16%（p=0.0022）。
安全性數據
- 安全性良好： 三級或以上不良事件（TEAE）發生率：Sovleplenib組43%，安慰劑組59%。
- 主要重度不良事件： 溫自身免疫性溶血性貧血（18%對43%），上呼吸道感染（2%對11%）。
- 無因治療不良事件導致死亡或停藥： Sovleplenib組未見相關死亡或因TEAE停藥。
監管及市場動態
- 新藥申請進度： 中國藥監局（NMPA）於2026年4月受理Sovleplenib治療wAIHA之新藥申請（NDA），並納入優先審評。
- 突破性治療認定： 2026年3月獲NMPA授予「突破性治療」資格，加快審批。
- 全球權益： 和黃醫藥保留Sovleplenib全球開發及商業化權益，為長遠發展留足空間。
產業及市場意義
- 有望成為首個獲批wAIHA靶向治療藥物： 目前wAIHA尚無獲批靶向藥物，Sovleplenib如獲批，將填補巨大市場空白。
- 拓展至ITP適應症： Sovleplenib於自身免疫性血小板減少症（ITP）三期臨床亦已證實有效，NDA已於2026年2月獲優先審評。
- 潛在患者群龐大： 以ITP為例，中國現有43萬患者，每年新增4.1萬，約半數對現有治療反應不理想。
專家點評
北京協和醫院韓冰教授：「wAIHA治療方案數十年未有突破，患者往往需長期高劑量激素且頻繁復發…本次數據顯示，Syk通路靶向治療可實現溶血快速且持久控制，特別是顯著降低救援治療和輸血需求，對患者生活質量提升意義重大。」
對股東重大啟示
- 具價格敏感性重大事件： Sovleplenib臨床突破及監管快速推進，將成為和黃醫藥管線重要增長點，一旦獲批，將開啟wAIHA及ITP兩大未滿足醫療市場，對股價具潛在提升動能。
- 全球化潛力： 公司掌握全球權益，若中國成功上市，有望推動全球申報及合作，帶來進一步增值空間。
- 風險提示： 臨床及監管風險仍需關注，惟突破性認定及優先審評有助降低審批不確定性。
關於和黃醫藥
和黃醫藥（納斯達克/倫交所AIM: HCM；港交所：13）專注於創新靶向及免疫治療藥物，現已在中國推出三款藥品，首款產品已獲美、歐、日等多國上市批准。
免責聲明
免責聲明： 本文僅供參考，不構成任何投資建議。部分訊息來自公司截至2026年6月之公告。投資者請結合所有公開資訊及專業意見審慎決策，過往表現不代表未來結果。
